Cipla Limited has notified that the United States Food and Drug Administration (USFDA) conducted a 'current Good Manufacturing Practices' (cGMP) inspection at its Pithampur manufacturing facility from 6th – 17th February, 2023, via an exchange filing.
The company received 8 inspectional observations in Form 483 at the end of the inspection. The company will work closely with the USFDA and is committed to address these comprehensively within the stipulated time.
The disclosure is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
'Official Apology Trend' Takes Over The Internet: Big Brands Participate In Viral Social Media Strategy With Witty Creatives
Bihar Assembly Elections 2025: RJD Alleges Voting Disruption In Danapur, Says 'Thousands Of Voters Stranded As Boat Services Suspended' - VIDEO
Western Railway Officer Sachin Sharma Completes Prestigious Ironman Malaysia Triathlon
IND vs AUS 4th T20I: Team India Edge Past Australia By 48 Runs At Gold Coast To Take 2-1 Lead In Series
